Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments

CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present third quarter 2018 results and corporate developments in a conference call on Oct. 31, 2018 at 8 a.m. ET.

The investor presentation may be downloaded starting at 8 a.m. ET from the Events and Presentations page of the Investor Relations section of Intellia’s website at intelliatx.com.

U.S. callers should dial 866-548-4713 and use conference ID# 5893807, approximately five minutes before the call.

International callers should click here to access dial-in information and use conference ID# 5893807, approximately five minutes before the call.

A replay of the call will be available on Intellia’s website, beginning on Oct. 31, 2018 at 12 p.m. ET.

About Intellia Therapeutics

Vice President, Investor Relations

Jennifer Mound Smoter

Senior Vice President, External Affairs & Communications